HEADER HYDROLASE/HYDROLASE INHIBITOR 25-SEP-01 1K1U TITLE COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF TITLE 2 RESISTANCE COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE RETROPEPSIN; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: RETROPEPSIN, PR; COMPND 5 EC: 3.4.23.16; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 5 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS HIV-1 PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR B.MAHALINGAM,P.BOROSS,Y.-F.WANG,J.M.LOUIS,C.FISCHER,J.TOZSER,R.W AUTHOR 2 HARRISON,I.T.WEBER REVDAT 6 07-FEB-24 1K1U 1 REMARK REVDAT 5 27-OCT-21 1K1U 1 REMARK SEQADV SHEET REVDAT 4 13-JUL-11 1K1U 1 VERSN REVDAT 3 24-FEB-09 1K1U 1 VERSN REVDAT 2 01-APR-03 1K1U 1 JRNL REVDAT 1 10-JUL-02 1K1U 0 JRNL AUTH B.MAHALINGAM,P.BOROSS,Y.F.WANG,J.M.LOUIS,C.C.FISCHER, JRNL AUTH 2 J.TOZSER,R.W.HARRISON,I.T.WEBER JRNL TITL COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND JRNL TITL 2 MECHANISMS OF RESISTANCE. JRNL REF PROTEINS V. 48 107 2002 JRNL REFN ISSN 0887-3585 JRNL PMID 12012342 JRNL DOI 10.1002/PROT.10140 REMARK 2 REMARK 2 RESOLUTION. 1.55 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.55 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 83.8 REMARK 3 CROSS-VALIDATION METHOD : FREE R REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.196 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.194 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.265 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 1149 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : NULL REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.181 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.178 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.243 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 1004 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 19976 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1510 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 59 REMARK 3 SOLVENT ATOMS : 145 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1714.0 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 0.00 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 20 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 7250 REMARK 3 NUMBER OF RESTRAINTS : 6915 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.007 REMARK 3 ANGLE DISTANCES (A) : 0.023 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.028 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.040 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.046 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.011 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.000 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.063 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.000 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1K1U COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 29-SEP-01. REMARK 100 THE DEPOSITION ID IS D_1000014454. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 20-OCT-00 REMARK 200 TEMPERATURE (KELVIN) : 95 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : NSLS REMARK 200 BEAMLINE : X12B REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.00 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : ADSC REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 23017 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.550 REMARK 200 RESOLUTION RANGE LOW (A) : 25.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 83.8 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.55 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.58 REMARK 200 COMPLETENESS FOR SHELL (%) : 51.6 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.37500 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 40.48 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.15 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20-50% SATURATED AMMONIUM SULPHATE, REMARK 280 10% DMSO, 0.25M CITRATE/0.5M PHOSPHATE BUFFER, VAPOR DIFFUSION, REMARK 280 HANGING DROP, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 25.64000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 30.89000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 29.13500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 30.89000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 25.64000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 29.13500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5380 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9350 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -29.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 8 NE - CZ - NH1 ANGL. DEV. = -3.1 DEGREES REMARK 500 ARG A 41 CD - NE - CZ ANGL. DEV. = 8.9 DEGREES REMARK 500 ARG A 41 NE - CZ - NH1 ANGL. DEV. = 3.6 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 35 120.81 -37.94 REMARK 500 REMARK 500 REMARK: NULL REMARK 600 REMARK 600 HETEROGEN REMARK 600 REMARK 600 PEPTIDE INHIBITOR 0Q4 HAS A REDUCED PEPTIDE (-CH2-NH) INSTEAD REMARK 600 OF THE NORMAL PEPTIDE LINK (-CO-NH). REMARK 630 REMARK 630 MOLECULE TYPE: PEPTIDE-LIKE INHIBITOR REMARK 630 MOLECULE NAME: N-[(2R)-2-({N~5~-[AMINO(IMINIO)METHYL]-L-ORNITHYL-L- REMARK 630 VALYL}AMINO)-4-METHYLPENTYL]-L-PHENYLALANYL-L-ALPHA-GLUTAMYL-L- REMARK 630 ALANYL-L-NORLEUCINAMIDE REMARK 630 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 630 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 630 REMARK 630 M RES C SSSEQI REMARK 630 0Q4 B 301 REMARK 630 SOURCE: NULL REMARK 630 TAXONOMY: NULL REMARK 630 SUBCOMP: ARG VAL DC0 GLU ALA NLE NH2 REMARK 630 DETAILS: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 0Q4 B 301 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1K1T RELATED DB: PDB REMARK 900 RELATED ID: 1K2B RELATED DB: PDB REMARK 900 RELATED ID: 1K2C RELATED DB: PDB REMARK 999 REMARK 999 SEQUENCE REMARK 999 MUTATIONS Q7K, L33I, L63I, C67A, C95A, HAVE BEEN MADE TO REMARK 999 STABILIZE THE PROTEASE FROM AUTOPROTEOLYSIS, WHILE REMARK 999 RETAINING ACTIVITY SIMILAR TO WILD-TYPE HIV-1 PROTEASE DBREF 1K1U A 1 99 UNP P04587 POL_HV1B5 501 599 DBREF 1K1U B 101 199 UNP P04587 POL_HV1B5 501 599 SEQADV 1K1U LYS A 7 UNP P04587 GLN 507 SEE REMARK 999 SEQADV 1K1U ILE A 33 UNP P04587 LEU 533 SEE REMARK 999 SEQADV 1K1U ILE A 45 UNP P04587 LYS 545 ENGINEERED MUTATION SEQADV 1K1U ILE A 63 UNP P04587 LEU 563 SEE REMARK 999 SEQADV 1K1U ALA A 67 UNP P04587 CYS 567 SEE REMARK 999 SEQADV 1K1U MET A 90 UNP P04587 LEU 590 ENGINEERED MUTATION SEQADV 1K1U ALA A 95 UNP P04587 CYS 595 SEE REMARK 999 SEQADV 1K1U LYS B 107 UNP P04587 GLN 507 SEE REMARK 999 SEQADV 1K1U ILE B 133 UNP P04587 LEU 533 SEE REMARK 999 SEQADV 1K1U ILE B 145 UNP P04587 LYS 545 ENGINEERED MUTATION SEQADV 1K1U ILE B 163 UNP P04587 LEU 563 SEE REMARK 999 SEQADV 1K1U ALA B 167 UNP P04587 CYS 567 SEE REMARK 999 SEQADV 1K1U MET B 190 UNP P04587 LEU 590 ENGINEERED MUTATION SEQADV 1K1U ALA B 195 UNP P04587 CYS 595 SEE REMARK 999 SEQRES 1 A 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 A 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL ILE GLU GLU MET SER LEU PRO SEQRES 4 A 99 GLY ARG TRP LYS PRO ILE MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE ILE ILE GLU SEQRES 6 A 99 ILE ALA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU MET THR SEQRES 8 A 99 GLN ILE GLY ALA THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 B 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL ILE GLU GLU MET SER LEU PRO SEQRES 4 B 99 GLY ARG TRP LYS PRO ILE MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE ILE ILE GLU SEQRES 6 B 99 ILE ALA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU MET THR SEQRES 8 B 99 GLN ILE GLY ALA THR LEU ASN PHE HET 0Q4 B 301 118 HETNAM 0Q4 N-[(2R)-2-({N~5~-[AMINO(IMINIO)METHYL]-L-ORNITHYL-L- HETNAM 2 0Q4 VALYL}AMINO)-4-METHYLPENTYL]-L-PHENYLALANYL-L-ALPHA- HETNAM 3 0Q4 GLUTAMYL-L-ALANYL-L-NORLEUCINAMIDE HETSYN 0Q4 INHIBITOR ANALOGUES OF CA-P2 FORMUL 3 0Q4 C40 H70 N11 O8 1+ FORMUL 4 HOH *145(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLY B 186 THR B 191 1 6 SHEET 1 A 4 GLN A 2 ILE A 3 0 SHEET 2 A 4 THR B 196 ASN B 198 -1 O LEU B 197 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 N THR A 96 O ASN B 198 SHEET 4 A 4 GLN B 102 ILE B 103 -1 N ILE B 103 O LEU A 97 SHEET 1 B 8 LYS A 43 GLY A 49 0 SHEET 2 B 8 GLY A 52 ILE A 66 -1 O GLY A 52 N GLY A 49 SHEET 3 B 8 LEU A 10 ILE A 15 -1 O LYS A 14 N GLU A 65 SHEET 4 B 8 GLN A 18 LEU A 24 -1 O GLN A 18 N ILE A 15 SHEET 5 B 8 ILE A 84 ILE A 85 1 N ILE A 85 O LEU A 23 SHEET 6 B 8 VAL A 32 GLU A 34 -1 O VAL A 32 N ILE A 84 SHEET 7 B 8 HIS A 69 GLY A 78 1 O LEU A 76 N ILE A 33 SHEET 8 B 8 GLY A 52 ILE A 66 -1 N ARG A 57 O VAL A 77 SHEET 1 C 8 TRP B 142 GLY B 149 0 SHEET 2 C 8 GLY B 152 ILE B 166 -1 O GLY B 152 N GLY B 149 SHEET 3 C 8 LEU B 110 ILE B 115 -1 O LYS B 114 N GLU B 165 SHEET 4 C 8 GLN B 118 LEU B 124 -1 O GLN B 118 N ILE B 115 SHEET 5 C 8 ILE B 184 ILE B 185 1 N ILE B 185 O LEU B 123 SHEET 6 C 8 VAL B 132 ILE B 133 -1 O VAL B 132 N ILE B 184 SHEET 7 C 8 HIS B 169 VAL B 177 1 O LEU B 176 N ILE B 133 SHEET 8 C 8 GLY B 152 ILE B 166 -1 N ARG B 157 O VAL B 177 SITE 1 AC1 40 ARG A 8 LEU A 23 ASP A 25 GLY A 27 SITE 2 AC1 40 ALA A 28 ASP A 29 ASP A 30 VAL A 32 SITE 3 AC1 40 ILE A 45 MET A 46 ILE A 47 GLY A 48 SITE 4 AC1 40 GLY A 49 ILE A 50 GLN A 58 VAL A 82 SITE 5 AC1 40 ILE A 84 ARG B 108 LEU B 123 ASP B 125 SITE 6 AC1 40 GLY B 127 ALA B 128 ASP B 129 ASP B 130 SITE 7 AC1 40 VAL B 132 ILE B 145 MET B 146 ILE B 147 SITE 8 AC1 40 GLY B 148 GLY B 149 ILE B 150 GLN B 161 SITE 9 AC1 40 PRO B 181 VAL B 182 ILE B 184 HOH B 540 SITE 10 AC1 40 HOH B 572 HOH B 580 HOH B 613 HOH B 633 CRYST1 51.280 58.270 61.780 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019501 0.000000 0.000000 0.00000 SCALE2 0.000000 0.017161 0.000000 0.00000 SCALE3 0.000000 0.000000 0.016186 0.00000